LABORATORY RESEARCH Hexokinase 2-Mediated Warburg Effect Is Required for PTEN– and p53-Deficiency-Driven Prostate Cancer Growth Building upon insights gained from their studies with Pten–/p53-deficient mouse embryonic fibroblasts, scientists report that hexokinase 2 is selectively upregulated by the combined loss of Pten and p53 in prostate cancer cells. [Cell Rep] Full Article | Graphical Abstract Luminal Cells Are Favored as the Cell of Origin for Prostate Cancer Scientists used a novel lineage-tracing strategy to assess the cell of origin in a diverse range of mouse models as well as a hormonal carcinogenesis model. Their results show that luminal cells are consistently the observed cell of origin for each model in situ; however, explanted basal cells from these mice can generate tumors in grafts. [Cell Rep] Full Article | Graphical Abstract Prostate Cancer Cells Home to Bone Using a Novel In Vivo Model: Modulation by the Integrin Antagonist GLPG0187 Micrometastasis is a barrier to the development of effective cancer therapies for prostate cancer metastasis to bone. Scientists aimed to establish a new model, allowing the tracking of prostate cancer cells homing to bone, and further, to evaluate the response of this approach to therapeutic modulation, using the integrin antagonist GLPG0187. [Int J Cancer] Abstract miR-130b Suppresses Prostate Cancer Metastasis through Down-Regulation of MMP2 Researchers found that the expression of miR-130b was significantly down-regulated in prostate cancer cell lines and clinical prostate cancer tissues. Enforced over-expression of miR-130b in prostate cancer cells suppressed whereas knock-down of miR-130b increased cell migration and invasion. [Mol Carcinog] Abstract Prostate Cancer Stem-Like Cells Proliferate Slowly and Resist Etoposide-Induced Cytotoxicity via Enhancing DNA Damage Response Researchers demonstrate that DU145-derived prostate cancer stem cells (PCSCs) progress slowly with more cells accumulating in the G1 phase in comparison to DU145 non-PCSCs. [Exp Cell Res] Abstract The Presence of Androgen Receptor Elements Regulates ZEB1 Expression in the Absence of Androgen Receptor Scientists demonstrate that a promoter construct containing both androgen response elements activates transcription of zinc finger E-box binding homeobox 1 (ZEB1) even in the androgen receptor (AR)-null cell lines DU145 and PC3. Incubation of the AR-positive cell line, LNCaP with R1881, failed to substantially increase the expression levels of ZEB1. [J Cell Biochem] Abstract Echinophora platyloba DC (Apiaceae) Crude Extract Induces Apoptosis in Human Prostate Adenocarcinoma Cells (PC 3) Scientists report the cytotoxicity and the mechanism of cell death of the methanolic extract prepared from E. platyloba plant against human prostate adenocarcinoma PC 3 cell line and human umbilical vein endothelial cells HUVEC cell line. [Biomed J] Abstract CLINICAL RESEARCH Active Monitoring, Radical Prostatectomy, or Radiotherapy for Localized Prostate Cancer: Study Design and Diagnostic and Baseline Results of the ProtecT Randomized Phase III Trial Researchers report the study design, participant sociodemographic and clinical characteristics, and the initial results of the testing and diagnostic phase of the Prostate testing for cancer and Treatment (ProtecT) trial, which aims to investigate the effectiveness of treatments for localized prostate cancer. [Lancet Oncol] Full Article Randomized Phase II Study of Bone-Targeted Therapy Containing Strontium-89 in Advanced Castrate-Sensitive Prostate Cancer Scientists showed that bone-targeted therapy using 1 dose of strontium-89 combined with chemohormonal ablation therapy did not favorably affect the progression-free survival of patients with castrate-sensitive prostate cancer. [Cancer] Abstract Serum Tri- and Tetra-Antennary N-Glycan Is a Potential Predictive Biomarker for Castration-Resistant Prostate Cancer A predictive biomarker for castration-resistant prostate cancer (CRPC) would provide useful information to physicians. Researchers evaluated the diagnostic potential of serum N-glycan profiling in CRPC. [Prostate] Abstract |